tri agonist glp 1 New strategies for the treatment of obesity and metabolic dysfunctions Calling retatrutide a “GLP-3” is

I dont see why one would take the path of a proper drug approval if there is now this less rigorous, alternative path to market, he said

PHGDH-mediated endothelial metabolism drives glioblastoma resistance to chimeric antigen receptor T cell immunotherapy

doi:10.1007/s00441-019-03016-8 Ilic S, Drmic D, Franjic S, et al

Summary GLP-1 RA originally emerged as drugs for the treatment of hyperglycemia and are currently licensed for the management of T2D and/or overweight/obesity

65,66 Compared with other NAFLD therapies, targeted GPCRs have outstanding advantages in the treatment of NAFLD

These higher-dose protocols have not been evaluated in human clinical trials, so there is no evidence that they are more effective than standard protocols